Eight innovative interventions to improve ART outcomes: Promising or sobering facts?

Precongress Course 15

MEFS MEFS Exchange course


Course coordinator(s)

Johnny Awwad (Sidra Medicine - Qatar) and Mohammad Aboulghar (Egyptian IVF-ET Center, Egypt)


Course type



Course description

Fertility treatment has come a long way in recent years, with significant technological developments and innovative interventions designed with the promise of improving the success rate and treatment experience for couples struggling with starting a family. Ground-breaking advancements have largely stemmed from extensive research in various experimental models before making their way into clinical practice. In addition to their intended goal of advancing our ability to alter reproductive pathways, these technologies have greatly expanded our understanding of the biology of reproduction. Some, nonetheless, have been hastily introduced into clinical practice with limited evidence to their usefulness, often driven by pressure to try promising innovations before the evidence is available to support their use. Such poorly validated clinical habits brisk of increasing dramatically IVF costs, reducing its affordability and access.

This precongress course discusses some of the innovative technologies which made their way into ART practice in recent years, with the prime focus of evaluating their clinical relevance to improving live births in view of emerging scientific evidence.


Target audience

Fertility specialists, urologists, embryologists, nurses, business partners, and legal professionals.


Educational needs and expected outcomes 

Expected educational outcomes and competencies: Interprofessional (Teams and Teamwork); Physician (Medical Knowledge, Practice-based Learning and Improvement).

After participating in this CME precongress activity, participants should be able to:

  • Describe the biologic pathways of growth hormone in ovarian folliculogenesis and assess its potential role in improving outcomes in poor responders.
  • Understand the working hypotheses for introducing oocyte mitochondrial transfer and evaluate the efficacy and safety of this practice.
  • Appraise the clinical evidence for the usefulness of adherence compounds in embryo transfer media and endometrial injury in enhancing endometrial receptivity.
  • Define the expanding indications for preimplantation genetic aneuploidy screening and their clinical effectiveness.
  • Describe the cost effectiveness of ‘freeze-all for all’ strategies in different clinical situations.
  • Describe the pathways of oocyte maturation and appraise the merits of oocyte in vitro maturation in modern ART practice.
  • Evaluate the possible role of platelet-rich plasma and mesenchymal stem cells strategies in enhancing endometrial receptivity and ovarian response.


Sunday 07 July 2024

Johnny Awwad, Qatar
09:00 - 09:30
Growth hormone for the poor responder: lessons learned from animal models and clinical trials?
Alexander Quaas, U.S.A.
09:30 - 09:45
09:45 - 10:15
Oocyte mitochondrial transfer to improve ART outcomes: safety versus efficacy?
Kutluk H. Oktay, U.S.A.
10:15 - 10:30
10:30 - 11:00
Coffee break
Chair invited, but not yet confirmed
11:00 - 11:30
Embryo glue: a riddle still unresolved?
Daniel Brison, United Kingdom
11:30 - 11:45
11:45 - 12:15
Endometrial scratching: to do or not to do?
Mohamed Aboulghar, Egypt
12:15 - 12:30
12:30 - 13:30
Lunch break
Mohamed Aboulghar, Egypt
13:30 - 14:00
The expanding indications of PGT A: Between hope and hype?
Elias Dahdouh, Canada
14:00 - 14:15
14:15 - 14:45
Freeze-all for all: one size fits all?
Yacoub Khalaf, United Kingdom
14:45 - 15:00
15:00 - 15:30
Coffee break
Michel Abou Abdallah, Lebanon
15:30 - 16:00
Oocyte in vitro maturation IVM: Has the time come?
Carlos Plancha, Portugal
16:00 - 16:15
16:15 - 16:45
Platelet-rich plasma PRP and Stem cells novelties in ART: Facts or Fads?
Johnny Awwad, Qatar
16:45 - 17:00